InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has completed a $150 million underwritten offering of 75 million ordinary shares at $2.00 per share. The proceeds will be used to advance the company's pipeline activities, including the development of izicopan and vilobelimab, as well as for working capital and general corporate purposes.
Key figures
- Deal Value Usd
- 150000000
- Offering Price
- 2
- Shares Offered
- 75000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.